Showing results (211-220 of 277) with videos related to

Sort By:
Pageof 28
Cell Death Discovery|March 6, 2026
ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapyZhenjun Li, Liangcheng Lv, Xiaoyu Yao, et al.
Leukemia|September 15, 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter studyYuqin Song, Quanli Gao, Huilai Zhang, et al.
Cancer Cell International|March 1, 2019
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphomaYalu Liu, Xiaogan Wang, Lijuan Deng, et al.
Cancers|September 10, 2021
The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell LymphomaXing Wang, Dedao Wang, Ning Ding, et al.
The ISME Journal|June 26, 2019
Recent mixing of Vibrio parahaemolyticus populationsChao Yang, Xiaoyan Pei, Yarong Wu, et al.
Bone Marrow Transplantation|December 8, 2022
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trialZhitao Ying, Yan Xie, Wen Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2020
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine KinaseYuqin Song, Keshu Zhou, Dehui Zou, et al.
The Lancet. Haematology|June 30, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trialYuqin Song, Yanyan Liu, Zhi-Ming Li, et al.
Future Oncology (London, England)|November 15, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaToby A Eyre, Nirav N Shah, Martin Dreyling, et al.
Leukemia & Lymphoma|October 6, 2022
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC studyBurhan Ferhanoglu, Tae Min Kim, Amado Karduss, et al.
Pageof 28